Elanco Makes Major Acquisition

Posted: Updated:
Elanco is headquartered in Greenfield. Elanco is headquartered in Greenfield.
GREENFIELD -

Greenfield-based Elanco Animal Health Inc. (NYSE: ELAN) is adding to its portfolio with a major acquisition. The company has announced plans to acquire Kansas-based Aratana Therapeutics (Nasdaq: PETX) in a deal valued at up to $245 million. In conjunction with the acquisition, Elanco has also announced the formation of a commercial team dedicated to the veterinary specialty business.

Elanco says the deal would allow it to integrate the Aratana portfolio of pet therapeutics into its companion animal therapeutics business. The company says, if the acquisition is completed, Aratana's portfolio would "significantly benefit" from Elanco's broader on-the-ground presence in the U.S.

"This proposed transaction acknowledges Aratana's contribution of pet therapeutics to the animal health industry, specifically recognizing our strong track-record as a drug developer and our field team's unmatched expertise delivering innovation to veterinary specialists," Craig Tooman, chief executive officer of Aratana, said in a news release. "As a newly independent, premier animal health company, we believe that Elanco would help expand our portfolio with their substantial resources and presence within the companion animal segment."

Elanco did not specify whether any jobs would be affected, with the exception that Aratana's field force would transition into the new commercial team.

The acquisition has been unanimously approved by the Aratana board of directors. The deal remains subject to approval by Aratana stockholders, as well as regulatory approvals and customary closing conditions.

Additionally, Elanco has announced it has signed a development and commercialization agreement with VetDC in Colorado for Tanovea-CA1, which is the first canine lymphoma treatment that has been conditionally approved by the U.S. Food and Drug Administration. Terms of the agreement were not disclosed.

“These agreements and the dedicated focus on the veterinary specialty sector fit perfectly into our overall strategic plan, furthering Elanco’s focus on companion animal therapy and better positioning us to capitalize on key underlying market fundamentals,” said Jeff Simmons, CEO of Elanco. “Thanks to advances in veterinary medicine, such as parasiticides and vaccines, pets are living longer and experience many of the same diseases of aging as humans, including arthritis and cancer. Further, consumers have an increasing expectation of care for these ailments. Our actions today enable us to take another step forward in fulfilling the needs of pet owners worldwide as they help their pets live longer, healthier, higher-quality lives.”

The acquisition is the first for Elanco since it was spun off from Indianapolis-based Eli Lilly and Co. (NYSE: LLY) as an independent, publicly-traded company.

  • Perspectives

    • Take Time to Face Reality

      When is the last time that you as a business owner truly stopped for 30 minutes or an hour and truly took some quiet time to reflect on your business? Like most owners, it’s probably been quite some time. We all get busy doing things, working hard, taking care of customers, running the business. But if we don’t take some time each day, week, month or quarter to slow down, we are setting ourselves up for failure. Business leaders and owners need the time to slow down to...

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • (Image provided by the Capital Improvement Board.)

      Indy Alters Plans for Downtown Hotels

      The city of Indianapolis has announced plans to change the framework for a major project in downtown Indy that has sparked controversy. The $120 million project, announced in October 2018, calls for an expansion of the Indiana Convention Center and two new hotels at Pan Am Plaza, which would add about 1,400 rooms. The project has drawn criticism from a group of hoteliers, who have expressed concern of a potential oversaturation in downtown Indy. Indianapolis Mayor Joe Hogsett issued...

    • (Photo Courtesy: Roche Diagnostics)

      Roche VP on List of Influential Women Executives

      An executive with Roche Diagnostics has joined an exclusive list of prominent and influential women, including Oprah Winfrey and Serena Williams.  Cindy Carlisle, Vice President of Human Resources at Roche Indy, was named to Savoy Magazine’s 2019 Most Influential Women in Corporate America. 

    • Shelly Timmons

      IU Health Names New Leader of Neurosurgery

      The Indiana University School of Medicine and IU Health Physicians have named Shelly Timmons to lead the department of neurosurgery. She previously served at Penn State Health Milton S. Hershey Medical Center as vice chair for administration in the department of neurosurgery and director of neurotrauma.  

    • Bank of America Merrill Lynch Adds Mar

      Bank of America Merrill Lynch has named Lucia Mar as senior vice president and the newly created position of Indiana market executive for Global Commercial Banking. She most recently served as market manager for the Greater Tennessee market in business banking. Prior to becoming a market manager, Mar was a senior relationship manager with the healthcare and institutions team.

    • Elanco is headquartered in Greenfield.

      Elanco Finishes Deal on Pet Therapeutics Purchase

      Greenfield-based Elanco Animal Health Inc.(NYSE: ELAN) completed its purchase Thursday of Aratana Therapeutics (Nasdaq: PETX), a pet therapeutics company located near Kansas City. As Inside INdiana Business first reported Tuesday Aratana shareholders voted overwhelmingly in favor of the $245 million deal.